Month: August 2024

There are numerous unanswered questions about GLP-1 medications, including their side effects, effectiveness over time, and their impact on health inequities among different patient groups. In response to these uncertainties, OMNY Health has initiated a new data network aimed at enriching understanding and enhancing the application of these drugs in diverse patient populations. OMNY Health, […]

Continue Reading

Inari Medical, a healthcare company, has initiated a recall of their ClotTriever XL catheters, a device used for removing clots and obstructions from major blood vessels outside the heart, according to a recent announcement by the Food and Drug Administration (FDA). This action comes after the identification of serious issues linked to the device, which […]

Continue Reading

Former President Donald Trump and Vice President Kamala Harris, potential contenders in a fierce political arena, have found common ground on one significant issue: the need for governmental intervention in reducing high U.S. drug prices. Despite their polarizing politics, both have exhibited a commitment to reining in the burgeoning costs that burden the American healthcare […]

Continue Reading

Insulet, a prominent medical device company, has gained significant regulatory approval from the Food and Drug Administration (FDA) for its latest insulin pump designed for use by individuals with Type 2 diabetes. This approval marks a pivotal development as it introduces the first automated insulin delivery (AID) system, frequently referred to as an “artificial pancreas,” […]

Continue Reading

In response to the recent declaration by the World Health Organization (WHO) classifying the mpox outbreak as a public health emergency of international concern, Roche has announced its commitment to enhance laboratory capacities globally for mpox testing. This announcement came as the new strain of mpox, identified as clade 1b, emerges rapidly in the Democratic […]

Continue Reading

Eli Lilly’s clinical trial for its metabolic disorder drug, tirzepatide, has released promising preliminary results that underscore the medication’s potential in delaying the onset of type 2 diabetes in patients who are obese or overweight. This trial, the longest to date involving tirzepatide, also aimed at assessing its effectiveness in weight management among prediabetes participants. […]

Continue Reading

In recent years, GLP-1-based agonists (GLP-1s) have dramatically altered the landscape of obesity treatment, revealing substantial benefits beyond simple weight loss. Originally introduced about two decades ago as treatments for type 2 diabetes, researchers quickly noted that GLP-1s also facilitated significant weight loss. This serendipitous discovery led to the FDA approval of the first GLP-1 […]

Continue Reading

GLP-1 receptor agonist drugs have revolutionized the pharmaceutical landscape, particularly in the fields of Type 2 diabetes management and weight loss. Brands like Ozempic, Wegovy, Saxenda, Mounjaro, and Zepbound have been key players in reshaping treatment paradigms. Since the FDA’s 2021 approval of Wegovy for weight management, the use of these drugs has skyrocketed, with […]

Continue Reading

Courtney Lias has taken on the role of the permanent Director of the Office of Health Technology 7 (OHT7) at the Center for Devices and Radiological Health (CDRH), following her tenure as Acting Director after Tim Stenzel’s departure at the end of 2023. Lias officially announced her new position during a conference in Washington D.C. […]

Continue Reading

MAUI, an ultrasound imaging company based in Arizona, recently announced its emergence from stealth mode, coinciding with the securing of a substantial $4 million contract from the Department of Defense (U.S. Army Medical Research and Development Command). This contract is focused on incorporating MAUI’s autonomous ultrasound technology, known as the MAUI K3900, into the trauma […]

Continue Reading